Interleukin-1α and soluble interleukin-2 receptor during small cell lung cancer chemotherapy: comparison of high chemotherapy dose with rhGM-CSF and standard chemotherapy dose without rhGM-CSF-Reference-Cited by-同舟云学术

Interleukin-1α and soluble interleukin-2 receptor during small cell lung cancer chemotherapy: comparison of high chemotherapy dose with rhGM-CSF and standard chemotherapy dose without rhGM-CSF

Published:1995-10 Issue:2 Volume:13 Page:145-153
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Gautier Véronique,Pujol Jean-Louis,Michel François-Bernard

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference26 articles.

1. De Cremoux H for the French centers' lung group. Competing events determining relapse-free survival in limited small cell lung carcinoma;Arriagada;J Clin Oncol,1992

2. Initial chemotherapeutic doses and survival in patients with limited small cell lung cancer;Arrigada;N Engl J Med,1993

3. Human granulocyte colony stimulating factor: biologic activities and receptor characterization on hematopoietic cells and small cell lung cancer lines;Avalos;Blood,1990

4. Actions of hematopoietic colony-stimulating factors in vivo and in vitro;Broxmeyer;Pathol Immunopathol Res,1987

5. Soluble interleukin 2 receptor in lung cancer. An indirect marker of tumour activity?;Buccheri;Chest,1991

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. G-CSF therapy and catheter-related Gram-positive sepsis increase serum IL-2 receptor α level and may falsely suggest a relapse in children with soft tissue sarcomas unless serum beta2-microglobulin, lactate dehydrogenase and C-reactive protein levels are determined concomitantly;Cytokine;2011-09